Delcath Systems to Participate in Upcoming Investor Conferences
Business Wire•27/10/2026•08:30 ET
0
Key Highlights
- ➤Delcath Systems will attend three investor conferences in November 2026.
- ➤UBS Global Healthcare Conference webcast will be available on Delcath’s investor website.
- ➤HEPZATO KIT is FDA-approved for adult metastatic uveal melanoma patients meeting specified criteria.
- ➤CHEMOSAT is approved in Europe for percutaneous hepatic perfusion procedures.
Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences:
Get started
Create a free account to read the full story.